We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App





POC Electrical Sensing-Based Blood Testing Technology Unveiled at ADLM 2024

By LabMedica International staff writers
Posted on 30 Jul 2024

Chronus Health (Fremont, CA, USA) is showcasing its innovative platform powered by electrical sensing-based blood testing technology at the ADLM 2024 conference taking place in Chicago from July 28 to August 1. More...

Chronus has developed the first-of-a-kind electrical sensing-based, real-time blood testing system for use in urgent care centers, skilled nursing facilities, infusion centers, retail clinics, as well as primary care and specialty clinics. This technology will reduce the time to diagnosis and lower overall healthcare costs since blood samples are analyzed on-site rather than sent to central labs for analysis. Chronus’ platform can uniquely support cell counting, chemistry assays (electrolytes, small molecules, and proteins), and immunoassays (proteins). This comprehensive solution, often regarded as the “holy grail” of diagnostics, has remained elusive until now, as past attempts to miniaturize existing technologies have lacked technical feasibility and cost-effectiveness.

The world’s first real-time electrical blood test system offers significant advantages in cost, size, and simplicity through the use of electrical sensors that facilitate miniaturization and reduce complexity. By leveraging a proprietary electrical sensing approach that integrates microfluidic sensors, machine learning, and aptamers, Chronus is poised to be the first to successfully deliver a platform capable of testing multiple blood panels outside the central lab setting. With 60% of all blood tests conducted outside hospitals, the company is at the forefront of providing fast and accurate blood testing at the point of care, at a lower price point.

“No one likes waiting for blood test results – neither doctors nor patients or their families,” said Caesar Djavaherian, MD, Co-Founder and Chief Clinical Innovation Officer of Carbon Health. “Now we have a technology that can cost-effectively provide results at the point of care, leading to better patient outcomes and increased provider satisfaction. We look forward to launching a clinical trial using the Chronus system soon.”

“We are creating a new era for point-of-care testing, with a platform slated to revolutionize the diagnostics industry,” said Anand Parikh, CEO and Co-Founder of Chronus Health. “The foundation of processing lab work has remained the same for decades, and just as other industries have benefited from the innovation in electrical technology, so too will healthcare.”

Related Links:
Chronus Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.